|
Burlingame, CA, March 9th, 2009 – Igenica, Inc., an antibody therapeutics discovery company, today announced that it has closed a Series A financing with leading venture capital investors and appointed Dr. Mike Rothe as Chief Executive Officer. Dr. Rothe will leave his post as Managing Director and CSO of U3 Pharma AG to lead Igenica, Inc. The Series A round was led by The Column Group, and joined by 5AM Ventures and OrbiMed Advisors.
READ MORE...
|
